Form 4: MYOMO Chief Medical Officer Awarded Over 62,000 Restricted Stock Units

MYOMO, Inc. has reported that its Chief Medical Officer, Harry Kovelman, was granted 62,938 Restricted Stock Units (RSUs) under the company's 2018 Stock Option and Incentive Plan.

Summary

• Harry Kovelman, the Chief Medical Officer of MYOMO, INC. (MYO), acquired 62,938 shares of common stock.
• The transaction occurred on June 11, 2025, and the shares were acquired at a price of $0 per unit.
• These shares represent a grant of Restricted Stock Units (RSUs) under the Issuer's 2018 Stock Option and Incentive Plan.
• Following this transaction, Mr. Kovelman beneficially owns a total of 153,672 shares.
• The granted RSUs are scheduled to vest in three equal annual installments, with the first vesting date set for June 11, 2026.

Sentiment

Score: 7

Explanation: The grant of RSUs to a key executive is a positive signal for management alignment and retention, though it's a routine compensation event rather than a major financial announcement.

Positives

• The grant of Restricted Stock Units to a key executive like the Chief Medical Officer helps align management's long-term interests with those of the shareholders.
• This form of compensation is a common strategy for executive retention and motivation, encouraging continued dedication to the company's success.

Risks

• The future vesting of these RSUs could lead to a minor dilution of existing shareholder equity, although this is a standard aspect of equity compensation plans.

Future Outlook

The vesting schedule for the granted Restricted Stock Units extends over three years, indicating a commitment to retaining the Chief Medical Officer and aligning his incentives with the company's long-term performance.

Industry Context

The grant of Restricted Stock Units is a common and widely accepted form of executive compensation in the technology and medical device sectors, used to attract, retain, and incentivize key talent by aligning their financial interests with the company's stock performance.

Comparison to Industry Standards

• Granting Restricted Stock Units (RSUs) as a component of executive compensation is a standard practice across various industries, including medical technology, to foster long-term commitment and align executive incentives with shareholder value creation. While specific comparable companies or projects are not detailed in this filing, the mechanism of RSU grants is consistent with compensation strategies observed in companies like Medtronic, Stryker, or Intuitive Surgical, which frequently utilize equity awards to compensate their senior leadership.

Corporate Governance

Related Party Transactions

• The transaction represents an insider compensation event, specifically a grant of equity to a Chief Medical Officer, which is a common form of related party transaction within the scope of executive compensation.

Stakeholder Impact

• Shareholders: The RSU grant aligns the Chief Medical Officer's financial interests with shareholder value creation, potentially leading to improved long-term performance. However, it also represents a future dilutive event upon vesting.
• Employees: This grant may serve as a positive signal regarding the company's commitment to its leadership and its compensation philosophy, potentially boosting morale and retention across the organization.

Next Steps

• The granted Restricted Stock Units will begin vesting in three equal annual installments starting on June 11, 2026.

Key Dates

Keywords

MYOMO, MYO, SEC Form 4, Insider Transaction, Restricted Stock Units, RSU Grant, Executive Compensation, Stock Option Plan, Beneficial Ownership